Free Trial
OTCMKTS:BVNRY

Bavarian Nordic A/S (BVNRY) Stock Price, News & Analysis

$8.58
-0.07 (-0.81%)
(As of 05/20/2024 ET)
Today's Range
$8.56
$8.88
50-Day Range
$6.92
$8.65
52-Week Range
$5.95
$10.65
Volume
1,875 shs
Average Volume
5,184 shs
Market Capitalization
$2.01 billion
P/E Ratio
13.61
Dividend Yield
N/A
Price Target
N/A
BVNRY stock logo

About Bavarian Nordic A/S Stock (OTCMKTS:BVNRY)

Bavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 

BVNRY Stock Price History

BVNRY Stock News Headlines

Bavarian Nordic A/S (BV3A.SG)
Bavarian Nordic A/S (BVNRY)
BVNKF Bavarian Nordic A/S
See More Headlines
Receive BVNRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:BVNRY
CIK
N/A
Employees
1,379
Year Founded
1994

Profitability

Net Income
$214.09 million
Pretax Margin
12.92%

Debt

Sales & Book Value

Annual Sales
$1.02 billion
Cash Flow
$0.03 per share
Book Value
$4.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.01 billion
Optionable
Not Optionable
Beta
1.50

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Paul John Chaplin MSc (Age 57)
    Ph.D., CEO & President
    Comp: $2.09M
  • Mr. Henrik Juuel M.Sc. (Age 59)
    CFO & Executive VP
    Comp: $1.16M
  • Mr. Russell Thirsk M.Sc. (Age 56)
    Executive VP & COO
  • Mr. Rolf Sass Sørensen
    Vice President of Investor Relations & Communications
  • Ms. Anu Helena Kerns M.Sc. (Age 52)
    Executive VP and Chief People & Sustainability Officer
  • Mr. Jean-Christophe May M.B.A. (Age 57)
    Pharm.D., Executive VP & Chief Commercial Officer
  • Dr. Laurence De Moerlooze Ph.D. (Age 60)
    Executive VP & Chief Medical Officer

BVNRY Stock Analysis - Frequently Asked Questions

How have BVNRY shares performed in 2024?

Bavarian Nordic A/S's stock was trading at $8.7450 at the start of the year. Since then, BVNRY stock has decreased by 1.9% and is now trading at $8.5760.
View the best growth stocks for 2024 here
.

Are investors shorting Bavarian Nordic A/S?

Bavarian Nordic A/S saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 100 shares, a decrease of 87.5% from the April 15th total of 800 shares. Based on an average trading volume of 3,100 shares, the days-to-cover ratio is currently 0.0 days.
View Bavarian Nordic A/S's Short Interest
.

How were Bavarian Nordic A/S's earnings last quarter?

Bavarian Nordic A/S (OTCMKTS:BVNRY) announced its earnings results on Wednesday, March, 6th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.12. The business earned $353.27 million during the quarter, compared to analyst estimates of $340.71 million. Bavarian Nordic A/S had a trailing twelve-month return on equity of 16.11% and a net margin of 14.74%.

How do I buy shares of Bavarian Nordic A/S?

Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BVNRY) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners